Quoin Pharmaceuticals Ltd. (QNRX): Total Assets
$20.39M
As of 2025-12-31
$11.97M
As of 2026-06-30
+12.1%
3-year compound annual growth
+71.4%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $20.39M | +29.8% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $15.71M | +29.1% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $12.17M | -15.8% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $14.46M | +54.5% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $9.36M | +579.1% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $1.38M | n/a | 2022-04-14, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | 2025-12-31 | $20.39M | +29.8% |
| Nexentis Technologies Inc. (NXTS) | 2025-12-31 | $20.41M | +273.4% |
| Incannex Healthcare Inc. (IXHL) | 2025-06-30 | $20.45M | +19.9% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $20.27M | -14.8% |
| Jyong Biotech Ltd. (MENS) | 2025-12-31 | $20.78M | +226.4% |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | $21.06M | +179.3% |
| Annovis Bio, Inc. (ANVS) | 2025-12-31 | $21.08M | +51.4% |
| Propanc Biopharma, Inc. (PPCB) | 2025-06-30 | $19.63M | n/m |
| Galectin Therapeutics Inc (GALT) | 2025-12-31 | $19.53M | +11.6% |
Compare QNRX, NXTS, IXHL, EVFM side by side · Screen every company in Pharmaceutical Preparations ↗